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 Dear editor, 
Bronchiectasis is a chronic and progressive respiratory disease with multiple possible 
causes(1,2). Many require a specific therapy and so a systematic aetiologic evaluation is 
recommended by guidelines(3). Studies have shown wide heterogeneity in the proportion of 
different aetiologies identified between centres(4-8), which can be partially justified because 
of geographical risks factors, but may also reflect variations in testing practice or in the 
definitions of aetiology used(9). The proportion of patients classified as idiopathic varies (26-
74%) across the literature and this variability is likely to be somewhat linked to a lack of use of 
a standard aetiological algorithm.(4-8)  
Variation in the assignment of aetiology impacts on every aspect of epidemiological research 
into bronchiectasis, as well as clinical trials where the inclusion of patients with post-infective 
or idiopathic bronchiectasis is only meaningful if we have standardised methods of assigning 
these aetiologies.(2) The aim of this study was to create a bronchiectasis aetiology 
classification algorithm that could be applied objectively to different healthcare settings. This 
algorithm was tested in a multicentre database of bronchiectasis patients with the goal of 
improving the degree of agreement and alignment between different centres.  
An analysis of ten databases (Dundee, Edinburgh, Newcastle– United Kingdom; Haifa-Israel; 
Galway-Ireland; Leuven-Belgium; Athens-Greece; Monza-Italy; Barcelona-Spain; Serbia) of 
outpatients with BE was performed. Consecutive patients aged ≥18 years with a diagnosis of 
BE based on high-resolution computed tomographic scans were enrolled. Patients with cystic 
fibrosis or traction bronchiectasis due to pulmonary fibrosis were excluded. Local ethics 
committee approved the data collection at each site.  
Demographics, previous medical history, comorbidities, as well as radiological, laboratory and 
microbiological findings were recorded. At each location, the aetiological diagnosis made by 
the clinician was also recorded. Centres all followed a standard of care that was consistent 
with the British Thoracic Society (BTS) 2010 guidelines in terms of testing for underlying 
causes.(3) The method of assignment of aetiologies and co-morbidities has been previously 
reported.(10)  
An aetiological algorithm (figure 1-A) was generated based on the 2010 BTS guidelines. The 
initial assessment was required to have a documented evidence of BE in HRCT scan and a 
clinical history compatible with BE. All patients should then have completed a group of initial 
tests – complete blood count, protein electrophoresis, immunoglobulin levels (IgG, IgM, IgA, 
IgE), specific antibody levels (against tetanus toxoid, S. pneumoniae and H. inﬂuenzae type b), 
specific IgE and IgG/precipitins for Aspergillus fumigatus, bacterial and mycobacterial sputum 
culture and pulmonary function tests.(3)  
A set of “definitive diagnosis” aetiologies were assembled - Congenital airway defects, 
bronchial obstruction (e.g due to tumour or foreign body), primary immunodeficiency, 
connective tissue disease (CTD) related BE. If the patient had clinical suspicion of primary 
ciliary dyskinesia (PCD), CF, CFTR-Related disease, α1-antitrypsin (A1AT), inflammatory bowel 
disease, yellow nail syndrome or diffuse pan-bronchiolitis, additional testing was performed. If 
all the findings were compatible with one of these aetiologies, then a definitive diagnosis was 
achieved. If atypical features were present (in terms of clinical manifestations, symptoms 
onset age, radiological findings) or other aetiology was suspected, then another group of 
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entities would be analysed. This group was classified as “Possible diagnosis” and included 
allergic bronchopulmonary aspergillosis (ABPA), post nontuberculous mycobacteria infection, 
post tuberculosis, chronic obstructive pulmonary disease (COPD) (defined as described in (9)), 
asthma, gastro-oesophageal reflux disease (GORD)/aspiration, and secondary 
immunodeficiency. If one of these diseases was the only possible aetiology present and if there 
were no atypical features, we also considered this a definitive diagnosis. If this was not the 
case or if the suspected aetiology was not in this group, we had to consider a final group of 
“diagnosis of exclusion” where in the case of a plausible association to previous infection we 
have post-infective aetiology. To be considered idiopathic, all this diagnostic assessment 
should be performed with a negative result, otherwise we should designate the patient as “not 
appropriately tested”.  
This aetiological algorithm was then applied to the ten databases previously mentioned, and 
results in terms of aetiology were compared.   
A total of 2502 patients were accessed – 116 in Newcastle, 280 in Galway, 190 in Leuven, 113 
in Serbia, 494 in Dundee, 88 in Haifa, 94 in Athens, 204 in Barcelona, 608 in Edinburgh and 315 
in Monza. The median age was 64 years (age range – 18-97yr) with a majority of the 
population being over 65 years old (n=1404, 56.1%) and there was a female gender 
predominance (n=1539, 61.5%). Median Bronchiectasis Severity Index (BSI)(11) score was 7 
with a relatively homogenous distribution between the severity groups – Mild (n=744, 29.7%), 
Moderate (n=894, 35.7%), Severe (n=864, 34.5%).  
The global diagnosis made by clinicians and diagnosis after applying the algorithm, are 
presented on figure 1-B. A total of 1456 patients (58.2%) had an aetiological diagnosis made by 
the clinician. The most common aetiology, excluding idiopathic, was post-infective (n=427, 
17.7%) and COPD (n=235, 9.4%).  
After applying the aetiological algorithm, a significant reduction was seen in terms of 
idiopathic cases (n=1046, 41.8% vs n=726, 29.0%, p<0.0001). The number of patients with 
COPD as a BE aetiology was higher (n=373, 14.9%) and less post-infective cases were seen 
(n=349, 13.9%). A significantly higher number of GORD/aspiration cases were classified as 
probable aetiology – 109 cases (4.4%) versus only 15 cases (0.6%) considered by the clinicians. 
Moreover, CTD was also considered an aetiology more often – 237 cases (9.5%) versus 157 
(6.3%) diagnosed by the clinicians.  
These changes in aetiological classification were seen across all the centres. With the clinician 
diagnosis, we had 6 centres with more than 40% of idiopathic cases. That number went down 
to just one after applying the algorithm.  
These results show that by applying the same structured aetiological algorithm to a 
bronchiectasis patient group the number of idiopathic cases can be lowered substantially. We 
demonstrate that clinicians frequently diagnose idiopathic bronchiectasis in the presence of 
disease associated with bronchiectasis suggesting the need for standardized aetiological 
categorization. This study has some limitations, even though centres practiced the BTS 2010 
guideline testing algorithm, some testing particularly for CF, alpha-1 antitrypsin deficiency and 
PCD are still subject to “clinician suspicion” and so testing rates are highly variable between 
centres. In that matter, some of the patients considered as idiopathic could still be 
characterized as “not appropriately tested”. In some cases, the algorithm can erroneously 
replace the diagnostic uncertainty of the clinician, because some elements are only present in 
a full clinical history and not recorded in the databases. 
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One of the major limitations is that the association between some diseases and bronchiectasis 
remains speculative. Particularly asthma and GORD are regarded as possible aetiologies but 
are very common in the general population and so cannot be regarded as definitive 
aetiologies. How to incorporate such diseases or phenotypes into classification algorithms is 
likely to require further discussion and debate over time.(12,13) The recently published 
European Bronchiectasis Guidelines recommended testing for immunodeficiency and ABPA 
routinely in all patients but did not address aetiological diagnosis in more detail. Therefore we 
believe our study is timely and may be incorporated into future guidelines.(14) The strengths 
of this study are the very large number of patients and that multiple and diverse 
bronchiectasis centres were included. Our study was limited to adults only and cannot be 
applied to children under the age of 18 years. 
In summary, Idiopathic bronchiectasis should only be diagnosed after a thorough assessment 
with the exclusion of all the relevant clinical entities that could be related to bronchiectasis. 
The use of a standardized aetiological algorithm across all bronchiectasis centres, while 
imperfect, would improve the ability of reaching a diagnosis leading to a change in 
management in many cases and would enhance the ability to compare results of different 
studies from different centres.   
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 Dear editor, 
Bronchiectasis is a chronic and progressive respiratory disease with multiple possible 
causes(1,2). Many require a specific therapy and so a systematic aetiologic evaluation is 
recommended by guidelines(3). Studies have shown wide heterogeneity in the proportion of 
different aetiologies identified between centres(4-8), which can be partially justified because 
of geographical risks factors, but may also reflect variations in testing practice or in the 
definitions of aetiology used(9). The proportion of patients classified as idiopathic varies (26-
74%) across the literature and this variability is likely to be somewhat linked to a lack of use of 
a standard aetiological algorithm.(4-8)  
Variation in the assignment of aetiology impacts on every aspect of epidemiological research 
into bronchiectasis, as well as clinical trials where the inclusion of patients with post-infective 
or idiopathic bronchiectasis is only meaningful if we have standardised methods of assigning 
these aetiologies.(2) The aim of this study was to create a bronchiectasis aetiology 
classification algorithm that could be applied objectively to different healthcare settings. This 
algorithm was tested in a multicentre database of bronchiectasis patients with the goal of 
improving the degree of agreement and alignment between different centres.  
An analysis of ten databases (Dundee, Edinburgh, Newcastle– United Kingdom; Haifa-Israel; 
Galway-Ireland; Leuven-Belgium; Athens-Greece; Monza-Italy; Barcelona-Spain; Serbia) of 
outpatients with BE was performed. Consecutive patients aged ≥18 years with a diagnosis of 
BE based on high-resolution computed tomographic scans were enrolled. Patients with cystic 
fibrosis or traction bronchiectasis due to pulmonary fibrosis were excluded. Local ethics 
committee approved the data collection at each site.  
Demographics, previous medical history, comorbidities, as well as radiological, laboratory and 
microbiological findings were recorded. At each location, the aetiological diagnosis made by 
the clinician was also recorded. Centres all followed a standard of care that was consistent 
with the British Thoracic Society (BTS) 2010 guidelines in terms of testing for underlying 
causes.(3) The method of assignment of aetiologies and co-morbidities has been previously 
reported.(10)  
An aetiological algorithm (figure 1-A) was generated based on the 2010 BTS guidelines. The 
initial assessment was required to have a documented evidence of BE in HRCT scan and a 
clinical history compatible with BE. All patients should then have completed a group of initial 
tests – complete blood count, protein electrophoresis, immunoglobulin levels (IgG, IgM, IgA, 
IgE), specific antibody levels (against tetanus toxoid, S. pneumoniae and H. inﬂuenzae type b), 
specific IgE and IgG/precipitins for Aspergillus fumigatus, bacterial and mycobacterial sputum 
culture and pulmonary function tests.(3)  
A set of “definitive diagnosis” aetiologies were assembled - Congenital airway defects, 
bronchial obstruction (e.g due to tumour or foreign body), primary immunodeficiency, 
connective tissue disease (CTD) related BE. If the patient had clinical suspicion of primary 
ciliary dyskinesia (PCD), CF, CFTR-Related disease, α1-antitrypsin (A1AT), inflammatory bowel 
disease, yellow nail syndrome or diffuse pan-bronchiolitis, additional testing was performed. If 
all the findings were compatible with one of these aetiologies, then a definitive diagnosis was 
achieved. If atypical features were present (in terms of clinical manifestations, symptoms 
onset age, radiological findings) or other aetiology was suspected, then another group of 
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entities would be analysed. This group was classified as “Possible diagnosis” and included 
allergic bronchopulmonary aspergillosis (ABPA), post nontuberculous mycobacteria infection, 
post tuberculosis, chronic obstructive pulmonary disease (COPD) (defined as described in (9)), 
asthma, gastro-oesophageal reflux disease (GORD)/aspiration, and secondary 
immunodeficiency. If one of these diseases was the only possible aetiology present and if there 
were no atypical features, we also considered this a definitive diagnosis. If this was not the 
case or if the suspected aetiology was not in this group, we had to consider a final group of 
“diagnosis of exclusion” where in the case of a plausible association to previous infection we 
have post-infective aetiology. To be considered idiopathic, all this diagnostic assessment 
should be performed with a negative result, otherwise we should designate the patient as “not 
appropriately tested”.  
This aetiological algorithm was then applied to the ten databases previously mentioned, and 
results in terms of aetiology were compared.   
A total of 2502 patients were accessed – 116 in Newcastle, 280 in Galway, 190 in Leuven, 113 
in Serbia, 494 in Dundee, 88 in Haifa, 94 in Athens, 204 in Barcelona, 608 in Edinburgh and 315 
in Monza. The median age was 64 years (age range – 18-97yr) with a majority of the 
population being over 65 years old (n=1404, 56.1%) and there was a female gender 
predominance (n=1539, 61.5%). Median Bronchiectasis Severity Index (BSI)(11) score was 7 
with a relatively homogenous distribution between the severity groups – Mild (n=744, 29.7%), 
Moderate (n=894, 35.7%), Severe (n=864, 34.5%).  
The global diagnosis made by clinicians and diagnosis after applying the algorithm, are 
presented on figure 1-B. A total of 1456 patients (58.2%) had an aetiological diagnosis made by 
the clinician. The most common aetiology, excluding idiopathic, was post-infective (n=427, 
17.7%) and COPD (n=235, 9.4%).  
After applying the aetiological algorithm, a significant reduction was seen in terms of 
idiopathic cases (n=1046, 41.8% vs n=726, 29.0%, p<0.0001). The number of patients with 
COPD as a BE aetiology was higher (n=373, 14.9%) and less post-infective cases were seen 
(n=349, 13.9%). A significantly higher number of GORD/aspiration cases were classified as 
probable aetiology – 109 cases (4.4%) versus only 15 cases (0.6%) considered by the clinicians. 
Moreover, CTD was also considered an aetiology more often – 237 cases (9.5%) versus 157 
(6.3%) diagnosed by the clinicians.  
These changes in aetiological classification were seen across all the centres. With the clinician 
diagnosis, we had 6 centres with more than 40% of idiopathic cases. That number went down 
to just one after applying the algorithm.  
These results show that by applying the same structured aetiological algorithm to a 
bronchiectasis patient group the number of idiopathic cases can be lowered substantially. We 
demonstrate that clinicians frequently diagnose idiopathic bronchiectasis in the presence of 
disease associated with bronchiectasis suggesting the need for standardized aetiological 
categorization. This study has some limitations, even though centres practiced the BTS 2010 
guideline testing algorithm, some testing particularly for CF, alpha-1 antitrypsin deficiency and 
PCD are still subject to “clinician suspicion” and so testing rates are highly variable between 
centres. In that matter, some of the patients considered as idiopathic could still be 
characterized as “not appropriately tested”. In some cases, the algorithm can erroneously 
replace the diagnostic uncertainty of the clinician, because some elements are only present in 
a full clinical history and not recorded in the databases. 
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One of the major limitations is that the association between some diseases and bronchiectasis 
remains speculative. Particularly asthma and GORD are regarded as possible aetiologies but 
are very common in the general population and so cannot be regarded as definitive 
aetiologies. How to incorporate such diseases or phenotypes into classification algorithms is 
likely to require further discussion and debate over time.(12,13) The recently published 
European Bronchiectasis Guidelines recommended testing for immunodeficiency and ABPA 
routinely in all patients but did not address aetiological diagnosis in more detail. Therefore we 
believe our study is timely and may be incorporated into future guidelines.(14) The strengths 
of this study are the very large number of patients and that multiple and diverse 
bronchiectasis centres were included. Our study was limited to adults only and cannot be 
applied to children under the age of 18 years. 
In summary, Idiopathic bronchiectasis should only be diagnosed after a thorough assessment 
with the exclusion of all the relevant clinical entities that could be related to bronchiectasis. 
The use of a standardized aetiological algorithm across all bronchiectasis centres, while 
imperfect, would improve the ability of reaching a diagnosis leading to a change in 
management in many cases and would enhance the ability to compare results of different 
studies from different centres.   
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Figure 1 –  A - Aetiology algorithm;  B - Aetiology results, clinician diagnosis and results after 
aetiological algorithm.   *  note these diagnoses can also be complications or co-morbidities 
(e.g ABPA can complicate existing bronchiectasis) 
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